Clinical Trials Browser

Phase 2 × Mesothelioma × LMB-100 × Clear all

NCT03644550 2021-12-02

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma